CVS to face barriers to entry in home dialysis – UBS

In a note, UBS says CVS Health’s (CVS -1.4%) potential entry into home dialysis may have limited success since patients will still need to work with a nephrologist and must belong to a clinic, requirements that CVS may struggle to match through its pharmacy network.

UBS adds that CVS may also have difficulty extricating itself from non-compete contracts and joint ventures with established dialysis providers.

DaVita (DVA -1.3%) and Fresenius Medical Care (FMS -2.6%) are still down, but above their session lows.

SA Authors rate CVS Bullish and DVA Neutral. The Quant rating for FMS is Neutral.

https://seekingalpha.com/news/3478461-cvs-face-barriers-entry-home-dialysis-ubs